Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Scientists have unlocked the mysteries of the 'extracellular matrix' which holds tumours together and the discovery could ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

The human body is teeming with trillions of symbiotic microorganisms, profoundly impacting our well-being. Within the gut, ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...